Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14066807 | 0.87 | TSHR (0.64) | TSHRCA1CA2CA9CA5A | |
| SCHEMBL28626490 | 0.87 | TSHR (0.64) | TSHRCA1CA2CA9CA5A | |
| SCHEMBL20565451 | 0.85 | TSHR (0.60) | TSHRCA1CA2CA9CA5A | |
| SCHEMBL2809758 | 0.83 | TSHR (0.89) | TSHRALDH1A1TDP1L3MBTL1CYP3A4 | |
| SCHEMBL5599951 | 0.83 | TSHR (0.89) | TSHRALDH1A1TDP1L3MBTL1CYP3A4 | |
| SCHEMBL9729928 | 0.82 | ALDH1A1 (0.67) | TSHRCA1CA2CA9CA5A | |
| SCHEMBL2458287 | 0.79 | TSHR (0.65) | TSHRCA1CA2CA9CA5A | |
| SCHEMBL8900471 | 0.79 | TSHR (0.80) | TSHRCA1CA2CA9CA5A | |
| SCHEMBL29389335 | 0.78 | TSHR (1.00) | TSHRALDH1A1TDP1L3MBTL1CYP3A4 | |
| SCHEMBL186285 | 0.78 | TSHR (1.00) | TSHRALDH1A1TDP1L3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555032-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2020231917-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-8822707-B2 | Nucleophile assisting leaving groups | FLORIDA ATLANTIC UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822707-B2 | Nucleophile assisting leaving groups | FLORIDA ATLANTIC UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822707-B2 | Nucleophile assisting leaving groups | FLORIDA ATLANTIC UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20080221347-A1 | Oligoether, crown ether linked to an acyclic or cyclic group linked with a sulfonate or silanol leaving group to an alkyl group, an alkenyl group, an alkynyl group or an optionally substituted aromatic or heteroaryl group; stabilized leaving group is more easily displaced | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-11 | — | — | US | disclosed |
| US-20080221347-A1 | Oligoether, crown ether linked to an acyclic or cyclic group linked with a sulfonate or silanol leaving group to an alkyl group, an alkenyl group, an alkynyl group or an optionally substituted aromatic or heteroaryl group; stabilized leaving group is more easily displaced | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-11 | — | — | US | disclosed |
| US-20080221347-A1 | Oligoether, crown ether linked to an acyclic or cyclic group linked with a sulfonate or silanol leaving group to an alkyl group, an alkenyl group, an alkynyl group or an optionally substituted aromatic or heteroaryl group; stabilized leaving group is more easily displaced | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-11 | — | — | US | disclosed |
| WO-2006060142-A2 | NUCLEOPHILE ASSISTING LEAVING GROUPS | FLORIDA ATLANTIC UNIVERSITY (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221347-A1 | Oligoether, crown ether linked to an acyclic or cyclic group linked with a sulfonate or silanol leaving group to an alkyl group, an alkenyl group, an alkynyl group or an optionally substituted aromatic or heteroaryl group; stabilized leaving group is more easily displaced | OSTC, STS, TST | TSHR 722/4885CA1 1963/4885CA2 1163/4885 |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, SLC10A2 | TSHR 995/4885CA1 1879/4885CA2 1728/4885 |
| US-11555032-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | SLC10A1, NR1H4, SLC10A2 | TSHR 995/4885CA1 1879/4885CA2 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.